Regulatory risk Calloway Labs faces regulatory scrutiny evidenced by a past False Claims Act and Anti-Kickback settlement, signaling a potential need for enhanced compliance, audit readiness, and robust documentation services to mitigate future risk.

Acquisition edge Ownership by Ampersand Capital Partners positions Calloway with backing for growth, potential access to cross-sell opportunities across portfolio companies, and a heightened willingness to engage in scalable, technology-driven services.

Tech-forward The lab emphasizes advanced testing technologies (in-house GC/MS, high volume screening, MRO integration, online result delivery), suggesting opportunities for offering complementary lab IT integrations, data analytics, and workflow optimization solutions.

Growth potential With a revenue range of 25–50 million and a growing footprint in clinical toxicology, there is opportunity to upsell broader toxicology panels, compliance solutions, and payer liaison services to expand market share.

Industry positioning As a fast-growing, mid-sized lab serving treatment and medical professionals, Calloway can be targeted for partnerships around regulatory education, training services, and scalable testing protocols to align with evolving treatment guidelines.